Tonix Pharmaceuticals presented data, analyses of TNX-102 SL treatment effects

Tonix Pharmaceuticals (TNXP) presented data in a poster presentation at the Annual European Congress of Rheumatology, EULAR, 2025, held June 11-14, 2025, in Barcelona, Spain. A copy of the Company’s poster, titled “Advancing Fibromyalgia Treatment: Transmucosal Sublingual Cyclobenzaprine, TNX-102 SL, Targets Non-restorative Sleep and Provides Sustained Pain Reduction.” TNX-102 SL is a non-opioid analgesic designed for daily bedtime dosing with an FDA Prescription Drug User Fee Act, PDUFA, goal date of August 15, 2025. TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two double-blind randomized placebo-controlled Phase 3 studies.